Collegium Pharmaceutical is rated a Buy after a guidance cut and stock drop, with the market pricing in an overly pessimistic ...

Companies are required to warn that experimental peptides, which haven’t been approved by the FDA, are for research use only.

People who experience chronic pain know how much it can impact their lives. New research shows that beyond the physical, ...

A new review confirms that beremagene geperpavec, the first FDA-approved topical gene therapy, significantly improves wound ...

The FDA has approved Tukysa (tucatinib) combined with trastuzumab and pertuzumab for the maintenance treatment of adult ...

Chronic pain care is shifting to indication-specific, non-opioid therapies, creating opportunities for durable treatments, precision tools and integrated care for aging populations.Dublin, Sept. 17, ...

NBC Selected independently determines what we cover and recommend. When you click on or buy through our links, we earn a commission. Learn more. Zoe Malin Reporter What are the different types of ...

Here’s how to differentiate between common types of pain and what experts recommend for managing them. By Allessandra DiCorato After the back, the knees are the second-most common site of chronic pain ...

If your pain gets worse after you take BELBUCA, do not take more of BELBUCA without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- ...

noticing your pain getting worse. If your pain gets worse after you take BELBUCA, do not take more of BELBUCA without first talking to your healthcare provider. Talk to your healthcare provider if the ...